GERALD DUNN: Open Payments
NPI 1407543481 · GOODYEAR, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,426 in 77 payments from 15 companies in 2025. Trend: 2023 $279 · 2024 $1,216 · 2025 $1,426
Food & beverage: $1,381Education: $45
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $197 |
| GlaxoSmithKline, LLC. | 10 | $177 |
| ABBVIE INC. | 10 | $165 |
| Lilly USA, LLC | 10 | $164 |
| Novo Nordisk Inc | 13 | $149 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $105 |
| Corcept Therapeutics | 4 | $100 |
| Astellas Pharma US Inc | 3 | $94 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $76 |
| Abbott Laboratories | 3 | $72 |
Products named: TRELEGY ELLIPTA, BREZTRI, UBRELVY, XIFAXAN, Korlym, Veozah, MOUNJARO, Kerendia.
Industry payments across AZ — which companies pay providers there.
